Skip to main content
PMC home page
Journal of Virology logoLink to Journal of Virology
. 1996 Jan;70(1):119–126. doi: 10.1128/jvi.70.1.119-126.1996

E2 represses the late gene promoter of human papillomavirus type 8 at high concentrations by interfering with cellular factors.

F Stubenrauch 1, I M Leigh 1, H Pfister 1
PMCID: PMC189795  PMID: 8523515

Abstract

The late gene promoter P7535 of the epidermodysplasia verruciformis-associated human papillomavirus type 8 (HPV8) is regulated by the viral E2 protein. Transfection experiments performed with the human skin keratinocyte cell line RTS3b and P7535 reporter plasmids revealed transactivation at low amounts and a repression of basal promoter activity at high amounts of E2 expression vector. This repression was promoter specific and correlated with the amount of transiently expressed E2 protein. Mutational analyses revealed that the negative regulation of P7535 activity is mediated by the low-affinity E2 binding site P2, which is separated by one nucleotide from the P7535 TATA box. Biochemical and genetic analyses suggested that repression is due to a displacement of the TATA-box binding protein by E2 and an interference of E2 with promoter-activating cellular factors that specifically recognize the P2 sequence. The high conservation of the P2 sequence among several papillomaviruses (epidermodysplasia verruciformis-associated HPVs, HPV1, cottontail rabbit papillomavirus, and bovine papillomavirus type 1) in the vicinity of the late gene promoter cap site suggests that an interplay of E2 and cellular factors at this sequence element is important for the expression of structural proteins.

Full Text

The Full Text of this article is available as a PDF (470.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Androphy E. J., Lowy D. R., Schiller J. T. Bovine papillomavirus E2 trans-activating gene product binds to specific sites in papillomavirus DNA. Nature. 1987 Jan 1;325(6099):70–73. doi: 10.1038/325070a0. [DOI] [PubMed] [Google Scholar]
  2. Barsoum J., Prakash S. S., Han P., Androphy E. J. Mechanism of action of the papillomavirus E2 repressor: repression in the absence of DNA binding. J Virol. 1992 Jun;66(6):3941–3945. doi: 10.1128/jvi.66.6.3941-3945.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Bernard B. A., Bailly C., Lenoir M. C., Darmon M., Thierry F., Yaniv M. The human papillomavirus type 18 (HPV18) E2 gene product is a repressor of the HPV18 regulatory region in human keratinocytes. J Virol. 1989 Oct;63(10):4317–4324. doi: 10.1128/jvi.63.10.4317-4324.1989. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bouvard V., Storey A., Pim D., Banks L. Characterization of the human papillomavirus E2 protein: evidence of trans-activation and trans-repression in cervical keratinocytes. EMBO J. 1994 Nov 15;13(22):5451–5459. doi: 10.1002/j.1460-2075.1994.tb06880.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Chomczynski P., Sacchi N. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 1987 Apr;162(1):156–159. doi: 10.1006/abio.1987.9999. [DOI] [PubMed] [Google Scholar]
  6. Demeret C., Yaniv M., Thierry F. The E2 transcriptional repressor can compensate for Sp1 activation of the human papillomavirus type 18 early promoter. J Virol. 1994 Nov;68(11):7075–7082. doi: 10.1128/jvi.68.11.7075-7082.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Dong G., Broker T. R., Chow L. T. Human papillomavirus type 11 E2 proteins repress the homologous E6 promoter by interfering with the binding of host transcription factors to adjacent elements. J Virol. 1994 Feb;68(2):1115–1127. doi: 10.1128/jvi.68.2.1115-1127.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Dong X. P., Stubenrauch F., Beyer-Finkler E., Pfister H. Prevalence of deletions of YY1-binding sites in episomal HPV 16 DNA from cervical cancers. Int J Cancer. 1994 Sep 15;58(6):803–808. doi: 10.1002/ijc.2910580609. [DOI] [PubMed] [Google Scholar]
  9. Dostatni N., Lambert P. F., Sousa R., Ham J., Howley P. M., Yaniv M. The functional BPV-1 E2 trans-activating protein can act as a repressor by preventing formation of the initiation complex. Genes Dev. 1991 Sep;5(9):1657–1671. doi: 10.1101/gad.5.9.1657. [DOI] [PubMed] [Google Scholar]
  10. Ensser A., Pfister H. Epidermodysplasia verruciformis associated human papillomaviruses present a subgenus-specific organization of the regulatory genome region. Nucleic Acids Res. 1990 Jul 11;18(13):3919–3922. doi: 10.1093/nar/18.13.3919. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fuchs P. G., Iftner T., Weninger J., Pfister H. Epidermodysplasia verruciformis-associated human papillomavirus 8: genomic sequence and comparative analysis. J Virol. 1986 May;58(2):626–634. doi: 10.1128/jvi.58.2.626-634.1986. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fuchs P. G., Pfister H. Transcription of papillomavirus genomes. Intervirology. 1994;37(3-4):159–167. doi: 10.1159/000150374. [DOI] [PubMed] [Google Scholar]
  13. Ham J., Dostatni N., Gauthier J. M., Yaniv M. The papillomavirus E2 protein: a factor with many talents. Trends Biochem Sci. 1991 Nov;16(11):440–444. doi: 10.1016/0968-0004(91)90172-r. [DOI] [PubMed] [Google Scholar]
  14. Ham J., Steger G., Yaniv M. Cooperativity in vivo between the E2 transactivator and the TATA box binding protein depends on core promoter structure. EMBO J. 1994 Jan 1;13(1):147–157. doi: 10.1002/j.1460-2075.1994.tb06244.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Haugen T. H., Turek L. P., Mercurio F. M., Cripe T. P., Olson B. J., Anderson R. D., Seidl D., Karin M., Schiller J. Sequence-specific and general transcriptional activation by the bovine papillomavirus-1 E2 trans-activator require an N-terminal amphipathic helix-containing E2 domain. EMBO J. 1988 Dec 20;7(13):4245–4253. doi: 10.1002/j.1460-2075.1988.tb03322.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hawley-Nelson P., Androphy E. J., Lowy D. R., Schiller J. T. The specific DNA recognition sequence of the bovine papillomavirus E2 protein is an E2-dependent enhancer. EMBO J. 1988 Feb;7(2):525–531. doi: 10.1002/j.1460-2075.1988.tb02841.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Hermonat P. L., Spalholz B. A., Howley P. M. The bovine papillomavirus P2443 promoter is E2 trans-responsive: evidence for E2 autoregulation. EMBO J. 1988 Sep;7(9):2815–2822. doi: 10.1002/j.1460-2075.1988.tb03137.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Horn S., Pfister H., Fuchs P. G. Constitutive transcriptional activator of Epidermodysplasia verruciformis-associated human papillomavirus 8. Virology. 1993 Oct;196(2):674–681. doi: 10.1006/viro.1993.1524. [DOI] [PubMed] [Google Scholar]
  19. Krubke J., Kraus J., Delius H., Chow L., Broker T., Iftner T., Pfister H. Genetic relationship among human papillomaviruses associated with benign and malignant tumours of patients with epidermodysplasia verruciformis. J Gen Virol. 1987 Dec;68(Pt 12):3091–3103. doi: 10.1099/0022-1317-68-12-3091. [DOI] [PubMed] [Google Scholar]
  20. Lambert P. F., Spalholz B. A., Howley P. M. A transcriptional repressor encoded by BPV-1 shares a common carboxy-terminal domain with the E2 transactivator. Cell. 1987 Jul 3;50(1):69–78. doi: 10.1016/0092-8674(87)90663-5. [DOI] [PubMed] [Google Scholar]
  21. Lees E., Osborn K., Banks L., Crawford L. Transformation of primary BRK cells by human papillomavirus type 16 and EJ-ras is increased by overexpression of the viral E2 protein. J Gen Virol. 1990 Jan;71(Pt 1):183–193. doi: 10.1099/0022-1317-71-1-183. [DOI] [PubMed] [Google Scholar]
  22. Luckow B., Schütz G. CAT constructions with multiple unique restriction sites for the functional analysis of eukaryotic promoters and regulatory elements. Nucleic Acids Res. 1987 Jul 10;15(13):5490–5490. doi: 10.1093/nar/15.13.5490. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. May M., Dong X. P., Beyer-Finkler E., Stubenrauch F., Fuchs P. G., Pfister H. The E6/E7 promoter of extrachromosomal HPV16 DNA in cervical cancers escapes from cellular repression by mutation of target sequences for YY1. EMBO J. 1994 Mar 15;13(6):1460–1466. doi: 10.1002/j.1460-2075.1994.tb06400.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. May M., Grassmann K., Pfister H., Fuchs P. G. Transcriptional silencer of the human papillomavirus type 8 late promoter interacts alternatively with the viral trans activator E2 or with a cellular factor. J Virol. 1994 Jun;68(6):3612–3619. doi: 10.1128/jvi.68.6.3612-3619.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. May M., Helbl V., Pfister H., Fuchs P. G. Unique topography of DNA-protein interactions in the non-coding region of epidermodysplasia verruciformis-associated human papillomaviruses. J Gen Virol. 1991 Dec;72(Pt 12):2989–2997. doi: 10.1099/0022-1317-72-12-2989. [DOI] [PubMed] [Google Scholar]
  26. McBride A. A., Byrne J. C., Howley P. M. E2 polypeptides encoded by bovine papillomavirus type 1 form dimers through the common carboxyl-terminal domain: transactivation is mediated by the conserved amino-terminal domain. Proc Natl Acad Sci U S A. 1989 Jan;86(2):510–514. doi: 10.1073/pnas.86.2.510. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. McBride A. A., Romanczuk H., Howley P. M. The papillomavirus E2 regulatory proteins. J Biol Chem. 1991 Oct 5;266(28):18411–18414. [PubMed] [Google Scholar]
  28. McBride A. A., Schlegel R., Howley P. M. The carboxy-terminal domain shared by the bovine papillomavirus E2 transactivator and repressor proteins contains a specific DNA binding activity. EMBO J. 1988 Feb;7(2):533–539. doi: 10.1002/j.1460-2075.1988.tb02842.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Monini P., Blitz I. L., Cassai E. Cooperative DNA binding of the bovine papillomavirus E2 transcriptional activator is antagonized by truncated E2 polypeptides. J Virol. 1993 Sep;67(9):5668–5676. doi: 10.1128/jvi.67.9.5668-5676.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Nasseri M., Gage J. R., Lorincz A., Wettstein F. O. Human papillomavirus type 16 immortalized cervical keratinocytes contain transcripts encoding E6, E7, and E2 initiated at the P97 promoter and express high levels of E7. Virology. 1991 Sep;184(1):131–140. doi: 10.1016/0042-6822(91)90829-z. [DOI] [PubMed] [Google Scholar]
  31. Pfister H. Human papillomaviruses and skin cancer. Semin Cancer Biol. 1992 Oct;3(5):263–271. [PubMed] [Google Scholar]
  32. Purdie K. J., Sexton C. J., Proby C. M., Glover M. T., Williams A. T., Stables J. N., Leigh I. M. Malignant transformation of cutaneous lesions in renal allograft patients: a role for human papillomavirus. Cancer Res. 1993 Nov 1;53(21):5328–5333. [PubMed] [Google Scholar]
  33. Romanczuk H., Thierry F., Howley P. M. Mutational analysis of cis elements involved in E2 modulation of human papillomavirus type 16 P97 and type 18 P105 promoters. J Virol. 1990 Jun;64(6):2849–2859. doi: 10.1128/jvi.64.6.2849-2859.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Rotenberg M. O., Chiang C. M., Ho M. L., Broker T. R., Chow L. T. Characterization of cDNAs of spliced HPV-11 E2 mRNA and other HPV mRNAs recovered via retrovirus-mediated gene transfer. Virology. 1989 Oct;172(2):468–477. doi: 10.1016/0042-6822(89)90189-x. [DOI] [PubMed] [Google Scholar]
  35. Sealey L., Chalkley R. At least two nuclear proteins bind specifically to the Rous sarcoma virus long terminal repeat enhancer. Mol Cell Biol. 1987 Feb;7(2):787–798. doi: 10.1128/mcb.7.2.787. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Stenlund A., Botchan M. R. The E2 trans-activator can act as a repressor by interfering with a cellular transcription factor. Genes Dev. 1990 Jan;4(1):123–136. doi: 10.1101/gad.4.1.123. [DOI] [PubMed] [Google Scholar]
  37. Stubenrauch F., Malejczyk J., Fuchs P. G., Pfister H. Late promoter of human papillomavirus type 8 and its regulation. J Virol. 1992 Jun;66(6):3485–3493. doi: 10.1128/jvi.66.6.3485-3493.1992. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Stubenrauch F., Pfister H. Low-affinity E2-binding site mediates downmodulation of E2 transactivation of the human papillomavirus type 8 late promoter. J Virol. 1994 Nov;68(11):6959–6966. doi: 10.1128/jvi.68.11.6959-6966.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Szymanski P., Stenlund A. Regulation of early gene expression from the bovine papillomavirus genome in transiently transfected C127 cells. J Virol. 1991 Nov;65(11):5710–5720. doi: 10.1128/jvi.65.11.5710-5720.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Tan S. H., Gloss B., Bernard H. U. During negative regulation of the human papillomavirus-16 E6 promoter, the viral E2 protein can displace Sp1 from a proximal promoter element. Nucleic Acids Res. 1992 Jan 25;20(2):251–256. doi: 10.1093/nar/20.2.251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Tan S. H., Leong L. E., Walker P. A., Bernard H. U. The human papillomavirus type 16 E2 transcription factor binds with low cooperativity to two flanking sites and represses the E6 promoter through displacement of Sp1 and TFIID. J Virol. 1994 Oct;68(10):6411–6420. doi: 10.1128/jvi.68.10.6411-6420.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Ushikai M., Lace M. J., Yamakawa Y., Kono M., Anson J., Ishiji T., Parkkinen S., Wicker N., Valentine M. E., Davidson I. trans activation by the full-length E2 proteins of human papillomavirus type 16 and bovine papillomavirus type 1 in vitro and in vivo: cooperation with activation domains of cellular transcription factors. J Virol. 1994 Oct;68(10):6655–6666. doi: 10.1128/jvi.68.10.6655-6666.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  43. Vande Pol S. B., Howley P. M. A bovine papillomavirus constitutive enhancer is negatively regulated by the E2 repressor through competitive binding for a cellular factor. J Virol. 1990 Nov;64(11):5420–5429. doi: 10.1128/jvi.64.11.5420-5429.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Journal of Virology are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES